Data as of Q4 2025 (Dec 31, 2025)
โณ
Showing Q2 2025 data
Camber Capital Management LP's Q4 2025 filing not yet available. Expected by Feb 14, 2026.

Camber Capital Management LP

โ€ขCIK: 1444043โ€ขFiling: Q2 2025

**Camber Capital Management LP** manages $1.1B across a concentrated portfolio of 25 positions. The fund exhibits significant exposure to the broad market via its top holding in SPY, valued at $308.9M. Further allocations are notable in healthcare and industrials, with substantial positions in ZBH ($91.2M), BAX ($86.3M), and HUM ($73.3M). This structure suggests a tactical, large-cap tilt within its current investment mandate.

Total AUM
$717.9M
+ $347.3M in options
QoQ Performance
-55.2%
Positions
23
+ 2 options
Top 10 Concentration
79.2%
Latest Filing
Q2 2025

Top Holdings Allocation

SPY
ZBH
BAX
HUM
CVS
SPY29.0%
ZBH8.6%
BAX8.1%
HUM6.9%
CVS6.8%
GMED4.4%
ICLR4.1%
ASND4.1%

๐Ÿ“ˆ Biggest Buys

ICLR
ICON PLC
NEW
4.1% of portfolio
MRK
MERCK & CO INC
NEW
3.7% of portfolio
UNH
UNITEDHEALTH GROUP INC
NEW
2.9% of portfolio
APLS
APELLIS PHARMACEUTICALS INC
NEW
1.4% of portfolio
BMRN
BIOMARIN PHARMACEUTICAL INC
+20.0%
3.1% of portfolio

๐Ÿ“‰ Biggest Sells

SPYPUT
SPDR S&P 500 ETF TR
-66.7%
29.0% of portfolio
ZBH
ZIMMER BIOMET HOLDINGS INC
-55.6%
8.6% of portfolio
HUM
HUMANA INC
-58.6%
6.9% of portfolio
BAX
BAXTER INTL INC
-50.4%
8.1% of portfolio
CVS
CVS HEALTH CORP
-53.3%
6.8% of portfolio

Sector Breakdown

Other47.3%
ETF29.0%
Healthcare23.7%

๐Ÿšช Exited Positionssold since Q1 2025

XBI
SPDR SER TR
SOLD
$162.2M
PTCT
PTC THERAPEUTICS INC
SOLD
$76.4M
CI
THE CIGNA GROUP
SOLD
$65.8M
โ€”
QIAGEN NV
SOLD
$56.2M
SRPT
SAREPTA THERAPEUTICS INC
SOLD
$51.1M
+5 more exited positions

Changes from Q1 2025

NEW4 new positions
โ†‘1 increased
โ†“17 decreased

Historical Filings

Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023